We have validated that hsa-miR-429 is indeed increased in bladder cancer [11], while it has been found that hsa-miR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer [12]. Here, CDH1 is linked to urinary bladder cancer.